Antonio Ceriello on Muck Rack

Antonio Ceriello

Barcelona
As seen in: Diabetes Research and Clinical Practice, Color Research & Application, Nature, Wiley, Wiley Online Library, SAGE Publishing, The Lancet, Diabetes Care Magazine, Diabetes Magazine, International Journal of Cardiology, RadcliffeCardiology.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Antonio

Contact Antonio, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Causes and consequences of discontinuation of GLP1RAs or tirzepatide

|
By Antonio Ceriello, Francesco Prattichizzo, Rosalba La Grotta, Cesare Celeste Berra, Barbara McGowan, Alicia Jenkins, Neale Cohen, Giuseppina Russo, Michael Albrecht Nauck
| Nature Verified
Abstract Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists and tirzepatide, a dual GLP1R and glucose-dependent insulinotropic polypeptide receptor agonist, have become fundamental in managing type 2 diabetes mellitus (T2DM) and obesity due to their potent glycaemia-lowering and weight-lowering effects as well as their cardiovascular and renal benefits.
Open in Who Shared Issue with article?

6. CARDIO-RENAL PROTECTION IN TYPE 2 DIABETES

|
By Stephen Colagiuri, Antonio Ceriello
| Diabetes Research and Clinical Practice Verified
Get full text access Log in, subscribe or purchase for full access. REFERENCES 1. Ibrahim, M. ∙ Ba-Essa, E.M. ∙ Baker, J. ... Cardio-renal-metabolic disease in primary care setting Diabetes Metab Res Rev. 2024; 40:e3755 2. Bello, A.K. ∙ Levin, A. ∙ Tonelli, M. ... Assessment of global kidney health care status JAMA. 2017; 317:1864-1881 3. World Health Organization. Web Annex A.
Open in Who Shared Issue with article?

4. BLOOD GLUCOSE-LOWERING THERAPIES - INSULIN OPTIONS FOR TYPE 2 DIABETES

|
By Stephen Colagiuri, Antonio Ceriello
| Diabetes Research and Clinical Practice Verified
Get full text access Log in, subscribe or purchase for full access. REFERENCES 1. World Health Organization (WHO). Keeping the 100-year-old promise: Making insulin access universal. Available from: https://www.who.int/publications/i/item/9789240039100 [Accessed August 2024]. 2. World Health Organization. Web Annex A. World Health Organization Model List of Essential Medicines – 23rd List, 2023.
Open in Who Shared Issue with article?
See all 54 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified